Αρχική World News Genetic Cancer Screenings in Younger Women May Be Cost-Effective and Lead to...

Genetic Cancer Screenings in Younger Women May Be Cost-Effective and Lead to Fewer Cases

Many women may wonder if they have genetic mutations that make them more apt to develop breast and ovarian cancers. Is it worth it for women to be tested and see if they may be carrying those mutations? A new study says it just might be, for those who are younger.

Woman at doctor
PHOTO: ADOBE STOCK/HERO IMAGES

According to a study published in JAMA Network Open, population-wide testing for genetic mutations connected with hereditary breast and ovarian cancers may be cost effective and have health benefits for women between 20 and 35. However, older women didn’t see the same benefits because most preventative surgeries happen before the age of 50 and most genetic cancer cases are diagnosed after age 50. Older women don’t have as much time to act.

The findings come from research done by the RISE Consortium, which works to determine the long-term health and economic benefit to genetic screening. Researchers developed a model to compare population screening for hereditary breast and ovarian cancers in an unselected population of women who had no prior diagnosis versus no screening. BRCA1 and BRCA2 were among the harmful mutations included.

Fewer Cancer Cases and Increased Quality of Life

The study found that population screening of 30-year-old women led to 75 fewer cancer cases per 100 thousand women. Among 45-year-olds, it wasn’t quite as effective, with only 24 fewer cases per 100 thousand women. Researchers also looked at quality-adjusted-life-years, or QALYs. They found that 30-year-old women gained 288 QALYs, while 45-year-old women only gained 97.

Woman getting mammogram
PHOTO: ADOBE STOCK/HERO IMAGES

Dr. Josh Peterson, one of the study authors and a principal investigator for RISE, says, “Screening for genetic conditions and risks has become common for the perinatal period, but whether to do so for adults is still debated. This study adds to the growing literature that testing for common genetic risks, such as hereditary breast and ovarian cancer, early in adult life is beneficial to patients and cost-effective from a societal perspective.”

The study authors noted that more research is needed to see if women who test negative still get recommended health screenings for all women.

Certain Genetic Mutations Greatly Increase Cancer Risk

According to the National Cancer Institute, 55%-72% of women who inherit a harmful BRCA1 mutation will develop breast cancer by the age of 70-80, while 45%-69% of those with a harmful BRCA2 mutation will. For ovarian cancer, those who have inherited the BRCA1 mutation have a 39-44% chance of developing the disease by age 70-80, and those with the BRCA2 mutation have an 11-17% chance.

Article continues below

Our Featured Programs

See how we’re making a difference for People, Pets, and the Planet and how you can get involved!

On an individual level, the United States Preventive Services Task Force recommends that women whose family members have these cancers be evaluated themselves to see if their family history may be associated with mutations. If it is, it may be helpful for the family member with the cancer to be tested first. Depending on those results, other family members may choose genetic counseling or to be tested.

Woman in laboratory
PHOTO: PIXABAY/JARMOLUK

Michelle has a broadcasting background, loves to write, and enjoys a good baseball game. You may find her on a hiking trail.

Provide Mammograms

Support those fighting Breast Cancer at The Breast Cancer Site for free!

Whizzco Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

Discovering the BRCA2 gene – 25 years on

A breast cancer cell. Credit: LRI EM Unit. 25 years ago, a team of our scientists were celebrating. Their risky strategy had paid off. “You...

Newly Developed RSClin Provides Prognostic Information in HR-positive, HER2-negative Early Breast Cancer

The online RSClin tool incorporating clinical-pathological data and the results of a 21-gene recurrence score (RS) was able to estimate the risk of distant...

Embracing Bravery When You Have a Genetic Cancer Disease

Emily Pinto Billcheck is a licensed social worker with experience in the mental health field. She is a von Hippel-Lindau (VHL) patient who inherited VHL from her...

Chemotherapy Administered for the First Diagnosed Testicular Cancer Reduces the Risk of Metachronous Contralateral Testicular Cancer Occurrence

Patients aged less than 30 years upon diagnosis of testicular cancer and those treated with surgery only are at higher risk of developing a...

New Research Looks for More Effective Breast Cancer Treatments for Black Women

Breast cancer affects people across all different backgrounds, but Black women in particular are more apt to get aggressive forms of the disease. They’re...

Palbociclib Plus Endocrine Therapy Does Not Improve PFS over Capecitabine in HR-positive, HER2-negative Aromatase Inhibitor Resistant Metastatic Breast Cancer

Although patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative, aromatase inhibitor resistant metastatic breast cancer maintained quality of life...